Ovid Therapeutics (OVID)
Develops targeted small molecules for neurological disorders involving neuronal hyperexcitability.
Something off on this page? Send us feedback.
Develops targeted small molecules for neurological disorders. Its pre-commercial pipeline combines GABA-AT and KCC2 programs with a partnership-led ROCK2 program, making clinical development and external collaboration central to its operating model.
Develops targeted small molecules for neurological disorders marked by neuronal hyperexcitability. Its pre-commercial pipeline includes OV329, a GABA-aminotransferase inhibitor for treatment-resistant focal-onset seizures and developmental and epileptic encephalopathies, and direct KCC2 activators such as OV4071 for CNS disorders.
A Graviton collaboration adds the OV888/GV101 ROCK2 program; Graviton is responsible through Phase 2 under joint oversight, with Ovid responsible afterward. The planned CCM Phase 2 initiation was paused as the partners evaluated competitor-trial learnings.
Work is concentrated in clinical development and mechanism selection rather than marketed products. Program progress depends on clinical development, external collaborations, and access to capital or co-development arrangements.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 11, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $4 | Target: $5 |
| Sep 3, 2026 | Roth Capital | Reiterate | Rating: —Target: $7 | Target: $8 |
| May 14, 2026 | Roth Capital | Target | Target: $3 | Target: $7 |
| Apr 9, 2026 | H.C. Wainwright | Target | Target: $2 | Target: $4 |
| Dec 11, 2025 | Roth Capital | Target | Target: — | Target: $3 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $117.2M · Total debt $12.7M · Total assets $232.0M · Shareholders' equity $209.9M
- Revenue
- $733.0K
- Operating income
- −$15.7M
- Net income
- −$15.0M
No dividends on record.
| Institutions | ≈ 75.38% | 147.22M shares | |
|---|---|---|---|
| 135 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.20% | 4.29M shares | |
| 7 holders · as of Jul 8, 2026 | |||
| Other | ≈ 22.42% | 43.79M shares | |
| remainder | |||
195.30M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Jupiter Topco LLCInstitution | 10.62% | 20.74M | as of Jun 30, 2026 |
Sirenia Capital Management LPInstitution | 9.23% | 18.03M | filed May 15, 2026 |
Eventide Asset Management, LLCInstitution | 6.05% | 11.81M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 5.54% | 10.82M | as of Jun 30, 2026 |
Ra Capital Management, L.P.Institution | 5.38% | 10.50M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Feb 23, 2026 | Jeffrey A. Rona | officer: CBFO | −8,541 | $1.45 |
| Feb 23, 2026 | Margaret A. Alexander | director, officer: President and CEO | −11,656 | $1.45 |
| Dec 11, 2025 | Jeremy M. Levin | director, officer: CEO | +82,904 | $1.40 |
- Xenon Pharmaceuticals
Late-stage oral therapy for focal-onset seizures
- Jazz Pharmaceuticals
Approved therapy across TSC and rare developmental epilepsies
- Praxis Precision Medicines
Investigational oral program for adult focal-onset seizures
- Stoke Therapeutics
Phase 3 RNA medicine for Dravet syndrome seizures
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Ovid Therapeutics | $2.47 | −10.69% | $515.1M | — | — | 325.4 | −88.3% |
| Xenon Pharmaceuticals | $36.27 | −7.21% | $3.78B | — | — | — | — |
| Jazz Pharmaceuticals | $232.49 | −3.36% | $15.11B | 16.4 | 9.2 | 3.3 | +15.6% |
| Praxis Precision Medicines | $283.35 | −5.75% | $8.38B | — | — | — | — |
| Stoke Therapeutics | $26.55 | −9.08% | $1.88B | — | — | 68.3 | −32.5% |
| Median | 16.4 | 9.2 | 35.8 | −8.5% |